Search clinical trials for: vadadustat

Total 30 results

Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Non-dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Effects of Iron Supplements on the Pharmacokinetics of MT-6548

Healthy

Japan
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (CONVERSION)

Anemia of Chronic Kidney Disease

United States
The University of Texas Health Science Center,...
United States Department of Defense; Akebia Therapeutics Inc.

Completed

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Coronavirus Infection | Acute Respiratory Distress Syndrome

United States
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland
Akebia Therapeutics

Completed

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (FO2RWARD-2)

Anemia | Dialysis-dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
Akebia Therapeutics

Completed

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Akebia Therapeutics

Completed

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Healthy Volunteers

Canada
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

Healthy

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

Healthy

United States
Akebia Therapeutics

Completed

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Pharmacokinetics | Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Withdrawn

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Banaras Hindu University

Completed

Amphotericin B Treatment in Visceral Leishmaniasis

Visceral Leishmaniasis

India

3

Subscribe